Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00386308 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety Study of XP12B in Women With Menorrhagia

A Phase 3 study of Menorrhagia and Heavy Menstrual Bleeding, sponsored by Ferring Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
196
Enrollment target
20
Study locations

NCT00386308: Completed Phase 3 study of Menorrhagia and Heavy Menstrual Bleeding, sponsored by Ferring Pharmaceuticals.

NCT00386308 is a Phase 3 study of Menorrhagia and Heavy Menstrual Bleeding that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 196 participants, roughly in line with the 209-participant average among 10 other Menorrhagia trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00386308, a Phase 3 study of Menorrhagia and Heavy Menstrual Bleeding, has completed, sponsored by Ferring Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
196 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.

Primary Outcome

reduction of menstrual blood loss in mL

Interventions

  • DRUG Tranexamic acid tablets
  • DRUG Placebo tablets

Study Locations (20)

Georgia

  • Investigative Site - Atlanta
  • Investigative Site - Atlanta
  • Investigative Site - Decatur
  • Investigative Site - Savannah

California

  • Investigative Site - Carmichael
  • Investigative Site - San Diego
  • Investigative Site - Upland

Florida

  • Investigative Site - Inverness
  • Investigative Site - Miami
  • Investigative Site - Miami

Arizona

  • Investigative Site - Tucson
  • Investigative Site - Tucson

Colorado

  • Investigative Site - Denver
  • Investigative Site - Lakewood

Connecticut

  • Investigative Site - Groton
  • Investigative Site - West Hartford

Louisiana

  • Investigative Site - Amite
  • Investigative Site - Baton Rouge

Arkansas

  • Investigative Site - Little Rock

Trial Details

FieldValue
Enrollment Target 196 participants
Start Date 2006-10
Est. Completion 2008-05
Phase Phase 3
Ferring Pharmaceuticals

83 total trials

What the finished NCT00386308 record still lists

NCT00386308 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 209-participant average among 10 other Menorrhagia trials with a reported enrollment target.

The record links to 2 conditions, with Menorrhagia appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic acid tablets is the first listed.

NCT00386308 names 20 study sites across 9 states, led by Georgia, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00386308 about?

NCT00386308 is a clinical study titled "Efficacy and Safety Study of XP12B in Women With Menorrhagia". The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.

What is the current status of trial NCT00386308?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2006-10. Estimated completion is 2008-05.

What conditions does trial NCT00386308 study?

This clinical trial studies the following conditions: Menorrhagia, Heavy Menstrual Bleeding.

What interventions are being tested in trial NCT00386308?

The interventions under investigation include: Tranexamic acid tablets (DRUG), Placebo tablets (DRUG).

Who is sponsoring clinical trial NCT00386308?

This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00386308 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menorrhagia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00386308's enrollment target sits among peer trials

196 5th of 10 higher than 6 of 10 other Menorrhagia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Menorrhagia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02822768 · 196 participants · NA

    Packing Versus no Packing for Cutaneous Abscess

  • NCT04250259 · 196 participants · Phase 2

    SAMe Trial for Patients With Alcoholic Cirrhosis

  • NCT05142592 · 196 participants · Phase 1

    Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

  • NCT05317832 · 196 participants · Phase 2

    Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00386308, the US trial registry maintained by the National Library of Medicine. NCT00386308 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.